Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been assigned an average recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $40.75.
Several equities analysts recently commented on COLL shares. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Needham & Company LLC lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Piper Sandler lowered Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Friday, May 10th.
View Our Latest Stock Report on Collegium Pharmaceutical
Insider Transactions at Collegium Pharmaceutical
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after buying an additional 17,942 shares in the last quarter. Pacer Advisors Inc. raised its stake in Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Collegium Pharmaceutical by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock valued at $31,987,000 after buying an additional 29,529 shares in the last quarter. LSV Asset Management raised its stake in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after buying an additional 291,286 shares in the last quarter.
Collegium Pharmaceutical Stock Performance
NASDAQ COLL opened at $36.08 on Monday. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $40.95. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 15.03 and a beta of 0.93. The business has a fifty day moving average of $32.64 and a 200-day moving average of $34.59. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. As a group, analysts predict that Collegium Pharmaceutical will post 5.57 earnings per share for the current fiscal year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Articles
- Five stocks we like better than Collegium Pharmaceutical
- ETF Screener: Uses and Step-by-Step Guide
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- P/E Ratio Calculation: How to Assess Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Following Congress Stock Trades
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.